1. Opening Hook
Remember when Ayurveda was just about neem and haldi? Well, Jeena Sikho’s “Acharya” just turned it into a ₹190 crore quarterly juggernaut. While FMCG giants fight for shelf space, Acharya Manish ji is selling wellness like it’s IPL merchandise — loud, fast, and with divine conviction. From “Om Arogyam Astu” to “EBITDA 48%,” this quarter had everything — chants, charts, and chaos. Grab your herbal tea — the real drama comes when investors start asking about beds, margins, and Chandan Diagnostics. 😏
2. At a Glance
- Revenue up 66% – From ₹114 crore to ₹190 crore; Ayurveda finally hit steroids (figuratively).
- EBITDA ₹92 crore, up 129% – Margins fatter than a festive ladoo box.
- PAT ₹59 crore, up 121% – Acharya ji’s blessings seem tax-exempt.
- Occupancy 57% – Beds are half-full, optimism is overflowing.
- 2,802 beds vs 1,600 YoY – Expansion faster than Baba Ramdev’s TV ads.
- Stock? – Traders already chanting “Om multibagger namah.”
3. Management’s Key Commentary
“We’ve achieved 66% growth year-on-year and 9% quarter-over-quarter.”
(Translation: Even Excel was surprised.)
“EBITDA margin at 48% shows our operational efficiency.”
(Translation: We’re making profits faster than hospitals can get fire NOCs.)
“We added 582 beds in six months — promised 2,800 for the year, already done.”
(Translation: Overachievement is our favorite yoga pose.)
“Tied up with Chandan Diagnostics; 34 centers active already.”
(Translation: Free blood tests, full diagnostics, and infinite footfalls — win-win, or at least that’s the mantra.)
“Our focus is to reach 7,000–10,000 beds in 3–5 years.”
(Translation: We plan hospitals like startups plan Series C.)
“We’re launching 15–20 OTC products including BP, sugar, and depression tablets.”
(Translation: FMCG
